International Journal of Tumor Therapy
p-ISSN: 2163-2189 e-ISSN: 2163-2197
2012; 1(4): 20-25
doi: 10.5923/j.ijtt.20120104.01
Vyacheslav Solovov, Leonid Shaplygin, Mikhail Vozdvizhenskiy, Ravil Khametov
Department of Interventional Radiology, Samara Regional Oncology Center, Samara, 443031, Russia
Correspondence to: Vyacheslav Solovov, Department of Interventional Radiology, Samara Regional Oncology Center, Samara, 443031, Russia.
Email: |
Copyright © 2012 Scientific & Academic Publishing. All Rights Reserved.
HIFU shows a successful treatment for localized prostate cancer. Here we explored the effectiveness of the HIFU treatment for the prostate cancer, hormone-resistant prostate cancer and failure after external beam radiotherapy and radical prostatectomy. 795 patients were treated in our centre in 2007 – 2012: Kaplan-Meir analyses of the total group indicated that the risk of progression was 23% after 5 years of follow-up. Our experience shows that HIFU ablation is safe, minimally invasive, effective treatment with moderate side effects for the PC, hormone-resistant prostate cancer, HIFU also may be used as a salvage therapy.
Keywords: HIFU, High Intensity Focused Ultrasound, Prostate Cancer
Cite this paper: Vyacheslav Solovov, Leonid Shaplygin, Mikhail Vozdvizhenskiy, Ravil Khametov, "High-Intensity Focused Ultrasound (HIFU) For the Prostate Cancer: 5-year Experience", International Journal of Tumor Therapy, Vol. 1 No. 4, 2012, pp. 20-25. doi: 10.5923/j.ijtt.20120104.01.
Figure 1. Physical principle of focused energy application |
Figure 2. Focal point adjustment: A) Penetration depth (19-26 mm; B) Latero-longitudinally (1.7 mm steps) |
Figure 3. HIFU devices: Ablatherm® |
|
|
Figure 4. Kaplan–Meier disease-free survival (DFS) curves according to risk group after HIFU |
[1] | Jemal A. et al. “Gender Statistics”. CA Cancer J. Clin, July 7, 2010. |
[2] | Chissov V, Starinsky V, Petrova G. “Malignant neoplasms in Russia in 2010 (morbidity and mortality)”, M. FGBU "MNIOI by Herzen "Ministry of Russia”, Russia, 2012. |
[3] | Prostate Cancer Treatment Guidelines, NCCN, v.1.2012. |
[4] | Tannock IF, Osoba D, Stockler MR, et al. “Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points”. J Clin Oncol, 1996, Vol.14, p.1756–64. |
[5] | Petrylak DP, Tangen CM, Hussain MH, et al. “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer”, N Engl J Med, 2004, Vol.351, p.1513–20. |
[6] | Tannock IF, de Wit R, Berry WR, et al. on behalf of the tax 327 Investigators. “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer”, N Engl J Med, 2004, Vol.351, p.1502–12. |
[7] | Thuroff S, Chaussy C, Vallancien G, et al. “High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multricentric study”, J Endourol, – t.17 (8), p.673-7, 2003. |
[8] | Lynn JG, Zwemer RL, Chick AJ, Miller AE. A new method for the generation and use of focused ultrasound in experimental biology. J Gen Physiol 1942; 26: 179-193 |
[9] | Fry WJ, Barnard JW, Fry EJ, Krumins RF, Brennan JF. Ultrasonic lesions in the mammalian central nervous system. Science 1955; 122: 517-518 |
[10] | Chaussy Ch., Thuroff S. “Transrectal high-intensuty focused ultrasound for local treatment of prostate cancer: current role”, Arch. Esp. Urol, 2011, vol.64 (6), p. 493-506. |
[11] | ter Haar G “Intervention and therapy”, Ultrasound Med Biol, 2000, 23 (Suppl 1), S51-S54. |
[12] | Chapelon JY et al. “Effects of high-energy focused ultrasound on kidney tissue in the rat and the dog”, Eur Urol, 1992, vol. 22, p.147-152. |
[13] | Uchida T et al. “Transrectal high-intensity focused ultrasound for treatment of patients with stage T1b-2n0m0 localized prostate cancer: a preliminary report”, Urology, 2002, vol.59, P.394–398. |
[14] | Chapelon JY et al. “New piezoelectric transducers for therapeutic ultrasound”, Ultrasound Med Biol, 2002, vol. 26, p.153-159. |
[15] | Curiel L et al. “1.5-D high intensity focused ultrasound array for non-invasive prostate cancer surgery”, IEEE Trans Ultrason Ferroelectr Freq Control, 2002, vol.49, p. 231–242. |
[16] | Tan JS et al. “Design of focused ultrasound phased arrays for prostate treatment”, Ultrasonics Symp Proc IEEE 2, 2002, p.1247–1251. |
[17] | Chavrier F et al. “Modeling of high intensity focused ultrasound-induced lesions in the presence of cavitation bubbles”, J Acoust Soc Am, 2000, vol.108, p. 432-440. |
[18] | Curiel L et al. “Experimental evaluation of lesion prediction modelling in the presence of cavitation bubbles: intended for high-intensity focused ultrasound prostate treatment”, Med Biol Eng Comput, 2004, vol.42, p. 44–54. |
[19] | Hynynen K et al. “A clinical, noninvasive, MR imaging-monitored ultrasound surgery method”, Radiographics, 1996, vol.16, p.185–195. |
[20] | Wu T et al. “Assessment of thermal tissue ablation with MR elastography”, Magn Reson Med, 2001, vol.45. P.80-87. |
[21] | Vaezy S et al. “Real-time visualization of high-intensity focused ultrasound treatment using ultrasound imaging”, Ultrasound Med Biol, 2001, vol.27, p.33-42. |
[22] | Sedelaar JPM et al. “The application of three-dimensional contrast-enhanced ultrasound to measure volume of affected tissue after HIFU treatment for localized prostate cancer”, Eur Urol, 2000, vol.37, p.559-568. |
[23] | Lu J et al. “In vitro measurement of speed of sound during coagulate tissue heating”, Ultrasonics Symp Proc IEEE 2, 1996, p.1299–1302. |
[24] | Thüroff S et al. “High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study”, J Endourol, 2003, vol.17, p.673-677. |
[25] | Rebillard X et al. “Treatment by HIFU of prostate cancer: survey of literature and treatment indications”, Prog Urol, 2003, vol.13, p.1428-1456. |
[26] | Djavan B., Moul J.W., Zlotta A. et al. “PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium”, Eur Urol., vol.43, № 1, p.12-27, 2003. |
[27] | Hellerstedt B.A., Pienta K.J. “The current state of hormonal therapy for prostate cancer”,C.A. Cancer J. Clin., vol. 52, p.154-179, 2002. |
[28] | Tannock IF, Osoba D, Stockler MR, et al. “Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points”, J Clin Oncol., Т.14, – p.1756–64, 1996. |
[29] | Petrylak DP, Tangen CM, Hussain MH, et al. “Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer”, N Engl J Med., Т.351, p.1513–20, 2004. |
[30] | Tannock IF, de Wit R, Berry WR, et al. “Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer”, N Engl J Med., T.351, p.1502–12, 2004. |
[31] | Blana A, MuratFJ, Walter B, Thuroff S, Wieland WF, Chaussy C, et al. “First analisys of the long-term result with High-intensity focused ultrasound with localised prostate cancer”, Eur. Urol., T. 53, p. 1194 –201, 2008. |
[32] | Uchida T, Shoji S, Nakano M, Hongo S, Nitta M, Murota A, Nagata Y. “Transrectal high-intensity focused ultrasound for the treatment of localized prostate cancer: eight-year experience”. Int J Urol., Nov. – T.16 (11), p.881–6, 2009. |
[33] | Gelet A, Chapelon JY, Bouvier R, Rouvie‘re O, Lyonnet D, Dubernard JM “Transrectal high intensity focused ultrasound for the treatment of localised prostate cancer: factors influencing the outcome”, Eur Urol., T. 40, p. 124–129, 2001. |